For the Inventor, By the Inventor

Enter inventor name

Hyderabad Telangana, India

Srikant Viswanadha

USPTO Granted Patents = 39 (Patent Applications = 12)

CIPO Patents = 6 (Patent Applications = 14)

EPO Patents = 14 (Patent Applications = 18)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 71(Granted Patents)

Location History:

Hyderabad, IN (US) (2014)
La Chaux-de-Fonds, CH (2018 - 2021)
Hyderabad, IN (2013 - 2024)

Company Filing History:

Rhizen Pharmaceuticals Sa

Incozen Therapeutics Pvt. Ltd.

Rhizen Pharmaceuticals Ag

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Loading Chart...

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428422 - Purine derivatives as SIK-3 inhibitors (2025-09-30),

2. 11858907 - Kinase modulators (2024-01-02),

3. 11466006 - Dual selective PI3 delta and gamma kinase inhibitors (2022-10-11),

4. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases (2021-07-20),

5. 11065236 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2021-07-20),

6. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),

7. 10851107 - Dual selective P13 delta and gamma kinase inhibitors (2020-12-01),

8. 10786504 - Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid (2020-09-29),

9. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),

10. 10611759 - Glutaminase inhibitors (2020-04-07),

11. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),

12. 10538501 - Kinase modulators (2020-01-21),

13. 10442783 - 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases (2019-10-15),

14. 10413532 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2019-09-17),

15. 10322130 - Substituted chromenones as modulators of protein kinases (2019-06-18),

Title: Unveiling the Innovations of Inventor Srikant Viswanadha

Introduction:

Inventor Srikant Viswanadha, hailing from Hyderabad, IN, has made a significant mark in the field of pharmaceutical inventions with a total of 38 patents to his name.

Latest Patents:

His latest patents showcase his pioneering work in the realm of kinase modulation. One notable invention is the PI3K protein kinase modulators, designed for the treatment, prevention, and amelioration of kinase-mediated diseases. Additionally, Viswanadha has also introduced dual selective PI3 delta and gamma kinase inhibitors, offering promising avenues for combating Pi3K kinase-related disorders.

Career Highlights:

During his illustrious career, Srikant Viswanadha has lent his expertise to renowned companies such as Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. His innovative contributions have not only shaped the pharmaceutical landscape but have also garnered recognition for his inventive prowess.

Collaborations:

Collaborating with esteemed coworkers like Meyyappan Muthuppalaniappan and Swaroop K Vakkalanka, Viswanadha has synergized his inventive capabilities to drive groundbreaking advancements in pharmaceutical research. Together, they have propelled the development of novel therapies and treatment modalities.

Conclusion:

In conclusion, Srikant Viswanadha's inventive acumen and dedication to pharmaceutical innovations have positioned him as a trailblazer in the field. His relentless pursuit of novel solutions underscores his commitment to revolutionizing healthcare and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…